Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Sep 2015
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Therapeutic Use
- Sponsors Cephalon
- 06 May 2011 Results presented at the 34th Annual Meeting of the Society of General Internal Medicine in May 2011, according to a Cephalon media release.
- 16 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2011 Results reported in a Cephalon media release.